Holmevis (Ibandronate Sodium Hydrate)

Holmevis is indicated for oral treatment of bone disorders in which excessive bone turnover leads to loss of bone strength.

• Osteoporosis in postmenopausal women and men at high risk of fracture.
• Osteoporosis in patients receiving glucocorticoid therapy.
• Paget's disease of bone to reduce abnormal bone remodeling.
• Long‑term management to maintain bone mineral density and reduce vertebral fracture risk.

• Ibandronate sodium hydrate belongs to the bisphosphonate class and binds with high affinity to hydroxyapatite crystals on bone surfaces. When osteoclasts attach to the bone matrix, the drug is internalized and inhibits farnesyl pyrophosphate synthase within the mevalonate pathway, preventing prenylation of small GTP‑binding proteins. This disruption reduces osteoclast maturation, activity, and survival, leading to decreased bone resorption and a net gain in bone mass.

Adverse reactions reported with oral ibandronate vary in frequency and severity.

Common

• Upper gastrointestinal discomfort such as dyspepsia, abdominal pain, or nausea.
• Transient musculoskeletal pain, including bone, joint, or muscle aches.
• Flu‑like symptoms such as fever, chills, or fatigue shortly after dosing.
• Mild headache or dizziness.
• Diarrhea or loose stools.
• Temporary rise in serum creatinine levels.

Serious

• Esophageal ulceration or severe esophagitis, especially if tablets are not taken with sufficient water.
• Acute phase reactions with severe fever, severe musculoskeletal pain, or allergic skin reactions.
• Severe hypersensitivity reactions such as anaphylaxis.

Before initiating Holmevis, clinicians should evaluate patient history and consider specific safety considerations to minimize risk.

• Ensure adequate hydration and take the tablet with at least 200 mL of water while remaining upright for at least 30 minutes.
• Avoid concomitant use of other oral bisphosphonates or medications that irritate the esophagus.
• Assess renal function; ibandronate is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min).
• Use caution in patients with a history of gastrointestinal disorders such as esophagitis, ulcers, or gastritis.
• Review calcium and vitamin D supplementation status to support bone health.
• Consider pregnancy status; the drug is not recommended during pregnancy or lactation due to unknown safety.
• Monitor for signs of hypocalcemia, especially in patients with impaired calcium metabolism.

Ibandronate may interact with other medicines, affecting absorption or increasing the risk of adverse events.

Avoid

• Concomitant oral calcium, iron, magnesium, or zinc supplements taken within 2 hours of the ibandronate dose, as they reduce drug absorption.
• Other bisphosphonates or potent anti‑resorptive agents, which may increase the risk of skeletal toxicity.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) or corticosteroids, which can exacerbate gastrointestinal irritation.
• Antacids containing aluminum or magnesium if taken too close to the dose.
• Renally cleared drugs such as aminoglycosides, requiring monitoring of renal function.
• Vitamin D analogues, which may potentiate calcium shifts and require serum calcium monitoring.